AOD9604 Research Guide: The hGH Fragment for Metabolic Research

AOD9604 occupies a unique position in the peptide research landscape as a compound that isolates one specific functional domain of human growth hormone — the lipolytic region — while deliberately excluding the domains responsible for growth hormone’s other biological activities. Derived from the C-terminal fragment of hGH (amino acids 176-191) with a critical tyrosine modification, AOD9604 enables researchers to study GH-mediated fat metabolism pathways in isolation, without the confounding effects of IGF-1 stimulation, glucose modulation, or cellular proliferation that full-length growth hormone would introduce.

This guide provides a thorough overview of AOD9604 for researchers — covering its molecular design rationale, the mechanism through which it activates lipolytic signaling independently of the GH receptor’s growth-promoting pathways, published research data, its relationship to the unmodified HGH Fragment 176-191, and practical handling protocols.

What Is AOD9604? Molecular Identity and Design

AOD9604 (Advanced Obesity Drug 9604) is a synthetic 16-amino acid peptide corresponding to the C-terminal region (amino acids 176-191) of human growth hormone (hGH), with a single but pharmacologically significant modification: the addition of a tyrosine residue at the C-terminus. This modification was engineered by researchers at Monash University in Melbourne, Australia, led by Professor Frank Ng, specifically to stabilize the lipolytic activity of the hGH fragment while maintaining its dissociation from growth-promoting signaling pathways.

AOD9604 Technical Specifications

• Full Name: AOD9604 / Advanced Obesity Drug 9604 / Tyr-hGH Fragment 176-191
• CAS Registry Number: 221231-10-3
• Molecular Weight: 1,815.08 g/mol
• Amino Acid Count: 16 residues (hGH 176-191 + C-terminal tyrosine)
• Sequence Origin: C-terminal fragment of human growth hormone (amino acids 176-191)
• Key Modification: Addition of tyrosine at C-terminus for enhanced lipolytic stability
• Physical Appearance: White to off-white lyophilized powder
• Solubility: Soluble in bacteriostatic water
• Stability: Good — moderate-sized peptide with straightforward handling requirements

The development of AOD9604 stemmed from a fundamental question in growth hormone biology: can the lipolytic (fat-metabolizing) effects of GH be separated from its growth-promoting, diabetogenic, and mitogenic effects? The answer, as demonstrated through the work of the Monash University group and subsequent published research, is yes — by isolating the specific structural domain of hGH responsible for lipolytic signaling.

Mechanism of Action: Lipolysis Without IGF-1

Understanding AOD9604’s mechanism requires understanding what it does and — equally important — what it does not do. The compound’s value as a research tool lies entirely in this selective activity profile.

What AOD9604 Does: Beta-3 Adrenergic Lipolytic Pathway

Published research has demonstrated that AOD9604 stimulates lipolysis (the breakdown of stored triglycerides in adipose tissue into free fatty acids and glycerol) through a mechanism involving the beta-3 adrenergic receptor signaling pathway. The proposed mechanism involves activation of adenylate cyclase in adipocytes, elevation of intracellular cAMP (cyclic adenosine monophosphate), and subsequent activation of hormone-sensitive lipase (HSL) — the enzyme directly responsible for hydrolyzing triglycerides stored in lipid droplets.

Additionally, published data indicates that AOD9604 inhibits lipogenesis — the synthesis of new fat from non-fat substrates. This dual action (stimulating fat breakdown while inhibiting fat synthesis) represents a two-pronged approach to modulating adipose tissue metabolism that distinguishes it from compounds that affect only one side of the fat metabolism equation. The lipolytic mechanism was characterized in published studies including work by Ng and Borstein (2000) in the International Journal of Obesity.

What AOD9604 Does NOT Do: No IGF-1, No Growth Effects

This is the critical distinction. Full-length human growth hormone (191 amino acids, ~22 kDa) activates the GH receptor and triggers JAK2-STAT5 signaling, leading to hepatic IGF-1 (insulin-like growth factor-1) production, cellular proliferation, bone growth, glucose counter-regulation, and numerous other downstream effects. AOD9604, comprising only amino acids 176-191, lacks the receptor-binding domains required for GH receptor activation and therefore:

• Does NOT stimulate IGF-1 production — no hepatic IGF-1 elevation, no growth-promoting signaling
• Does NOT affect blood glucose regulation — no diabetogenic counter-regulatory effects
• Does NOT promote cellular proliferation — no mitogenic activity associated with GH/IGF-1 axis activation
• Does NOT cause organ growth or acromegalic effects — no interaction with the GH receptor’s growth-promoting domains

This clean separation of lipolytic activity from growth-promoting activity is what makes AOD9604 a uniquely valuable research tool. Researchers can study GH-associated fat metabolism pathways in complete isolation, without any confounding effects from IGF-1, glucose modulation, or proliferative signaling.

Published Research: Key Studies and Applications

Preclinical Metabolic Studies

The foundational preclinical research on AOD9604 was conducted at Monash University under Professor Frank Ng’s research group. Published studies in obese animal models demonstrated reductions in body fat mass, decreases in circulating triglyceride levels, and inhibition of lipogenesis without any effects on IGF-1 levels, food intake, or lean body mass. The compound produced its lipolytic effects specifically in adipose tissue without systemic metabolic disruption — the exact selective profile its design intended to achieve. Key early findings were published in Ng and Borstein (2000) and subsequent papers from the Monash group.

Clinical Investigation

AOD9604 advanced to human clinical trials under the sponsorship of Metabolic Pharmaceuticals Ltd. Phase 2 clinical studies enrolled overweight and obese subjects to assess the compound’s safety, tolerability, and effects on body composition. Published safety data from these trials documented a favorable tolerability profile with an adverse event rate comparable to placebo, and importantly confirmed the preclinical finding that AOD9604 does not elevate IGF-1 levels or affect glucose homeostasis in human subjects. The clinical program generated the safety dataset that led to AOD9604 receiving GRAS (Generally Recognized As Safe) designation from the FDA in 2007 for specific applications.

Chondrocyte and Cartilage Research

An unexpected and emerging area of AOD9604 research involves its effects on chondrocytes (cartilage cells) and joint tissue. Published data suggests that AOD9604 may promote proteoglycan synthesis and reduce matrix metalloproteinase (MMP) activity in chondrocyte cultures — findings that have generated interest in potential applications for osteoarthritis and cartilage repair research. This is distinct from its lipolytic mechanism and represents an area of active investigation.

Bone Metabolism Research

Preliminary published data has also examined AOD9604’s effects on osteoblast (bone-forming cell) activity. While this research is at an earlier stage than the adipose and cartilage work, initial findings suggest potential effects on bone cell differentiation that may be relevant to musculoskeletal research applications beyond the compound’s primary metabolic focus.

AOD9604 vs HGH Fragment 176-191: What Is the Difference?

This is one of the most common questions from researchers, because both compounds derive from the same region of human growth hormone and are sometimes confused. The distinction is specific but pharmacologically important:

• AOD9604 is the hGH fragment 176-191 plus an additional C-terminal tyrosine residue. This tyrosine modification was engineered by the Monash University group to stabilize the lipolytic active conformation of the peptide, enhancing its metabolic activity and extending its effective research utility compared to the unmodified fragment.
• HGH Fragment 176-191 is the native, unmodified C-terminal fragment of human growth hormone — amino acids 176 through 191 as they exist in the full-length hGH protein, with no additional modifications.

Both compounds target the same lipolytic pathway and share the same fundamental mechanism. The practical difference is that AOD9604’s tyrosine modification provides improved metabolic stability and enhanced lipolytic potency in published comparative studies. Most current research protocols use AOD9604 rather than the unmodified fragment, though some researchers use both for direct comparison studies investigating the effect of the tyrosine modification itself.

AOD9604 in Context: How It Compares to Other Metabolic Peptides

vs GLP-1 Agonists (Semaglutide, Tirzepatide, Retatrutide)

AOD9604 and GLP-1 receptor agonists like Semaglutide, Tirzepatide, and Retatrutide represent fundamentally different approaches to metabolic research. GLP-1 agonists work through incretin receptor signaling — affecting insulin secretion, glucagon suppression, gastric emptying, and central appetite regulation. AOD9604 works through direct adipocyte lipolytic signaling without affecting any incretin, insulin, or appetite pathways. There is no mechanistic overlap between them, which is why some research protocols investigate them in combination to study the interaction of incretin-mediated metabolic effects with direct lipolytic stimulation. For detailed analysis of the GLP-1 compounds, see our Semaglutide vs Tirzepatide comparison and Retatrutide research guide.

vs Growth Hormone Secretagogues (Ipamorelin, CJC-1295)

GH secretagogues like Ipamorelin and CJC-1295 stimulate the pituitary to release endogenous full-length growth hormone, which then activates the complete spectrum of GH activities — including lipolysis, but also including IGF-1 elevation, glucose counter-regulation, and growth effects. AOD9604 provides access to only the lipolytic component without triggering the full GH cascade. Researchers studying GH-mediated fat metabolism specifically, without wanting IGF-1 or glucose confounders, use AOD9604; researchers studying the full GH axis use secretagogues. For detailed information on these compounds, see our Ipamorelin research guide and CJC-1295 research guide.

vs 5-Amino-1MQ

5-Amino-1MQ targets fat metabolism through an entirely different mechanism — it inhibits NNMT (nicotinamide N-methyltransferase), an enzyme involved in cellular energy metabolism and NAD+ homeostasis. Where AOD9604 directly stimulates adipocyte lipolysis through beta-3 adrenergic signaling, 5-Amino-1MQ modulates fat cell metabolism through NNMT inhibition and NAD+ pathway effects. They represent complementary research tools for investigating different aspects of adipose tissue biology.

Storage, Handling, and Reconstitution

Lyophilized Storage

Store lyophilized AOD9604 at -20°C in its original sealed vial. At 1,815 g/mol and 16 amino acids, AOD9604 falls in the small-to-moderate size range and exhibits good lyophilized stability for 18-24+ months at freezer temperature. For comprehensive storage protocols, see our Peptide Storage Guide.

Reconstitution

AOD9604 dissolves readily in bacteriostatic water without requiring acidified solvent. For a 5 mg vial, adding 2.5 mL of bacteriostatic water produces a working concentration of 2 mg/mL (2,000 mcg/mL). Use our free Peptide Reconstitution Calculator for custom volumes, or follow the complete step-by-step reconstitution protocol.

After Reconstitution

Store at 2-8°C and use within 21 days. AOD9604’s moderate size and absence of oxidation-sensitive residues contribute to reasonable solution stability. Aliquot into single-use volumes immediately after reconstitution for longer-term frozen storage at -20°C. For a complete guide to maximizing reconstituted peptide lifespan through aliquoting, see our storage guide.

Purchasing Research-Grade AOD9604

At Apex Laboratory, our AOD9604 is verified to ≥99% purity through dual HPLC and Mass Spectrometry analysis, confirming both chromatographic purity and correct molecular weight (1,815.08 g/mol, CAS 221231-10-3). We also carry the unmodified HGH Fragment 176-191 for comparative research, along with the complete GH-axis peptide lineup including Ipamorelin, CJC-1295, IGF-1 LR3, and Sermorelin. All ship same-day with ≥99% purity guaranteed. Visit our About page to learn about our dual verification quality process, or read our COA guide to understand how to evaluate analytical documentation.

Frequently Asked Questions

What is the difference between AOD9604 and HGH Fragment 176-191?

Both derive from the same C-terminal region (amino acids 176-191) of human growth hormone. The difference is that AOD9604 includes an additional tyrosine residue engineered at the C-terminus to stabilize the lipolytic active conformation and enhance metabolic potency. HGH Fragment 176-191 is the native, unmodified fragment. Most modern research protocols use AOD9604 due to the improved stability and activity provided by the tyrosine modification.

Does AOD9604 increase IGF-1 levels?

No. This is one of AOD9604’s defining characteristics. Published clinical data confirms that AOD9604 does not elevate IGF-1 levels because it lacks the structural domains required for GH receptor binding and JAK2-STAT5 signaling that drive hepatic IGF-1 production. This selective absence of IGF-1 stimulation is what makes AOD9604 valuable as a research tool for studying lipolysis in isolation from the broader GH/IGF-1 axis.

What is the CAS number and molecular weight of AOD9604?

AOD9604 has CAS registry number 221231-10-3 and a molecular weight of 1,815.08 g/mol. It consists of 16 amino acids corresponding to hGH residues 176-191 plus a C-terminal tyrosine modification.

What does the GRAS designation mean for AOD9604?

GRAS stands for “Generally Recognized As Safe” — a designation granted by the FDA based on scientific evidence that a substance is safe for its intended application. AOD9604 received GRAS status in 2007 based on the safety data generated during its clinical trial program. This designation reflects the compound’s safety profile as demonstrated in human studies but does not constitute approval as a drug or therapeutic agent.

Is AOD9604 approved for human therapeutic use?

No. Despite its GRAS designation and clinical trial data, AOD9604 has not been approved by the FDA or any regulatory agency as a therapeutic drug. The research-grade AOD9604 sold by Apex Laboratory is classified as a chemical research reagent intended strictly for in-vitro laboratory research and is not for human consumption.

Continue Your Research

• Ipamorelin Research Guide: The Selective Growth Hormone Secretagogue
• CJC-1295 Research Guide: With DAC vs Without DAC Explained
• Retatrutide: The Triple Agonist Peptide
• Semaglutide vs Tirzepatide: Mechanism, Research Data & Key Differences
• Peptide Reconstitution Calculator — Free Research Tool

Research Use Disclaimer

This article is provided for educational and research reference purposes only. AOD9604 and all products sold by Apex Laboratory are intended exclusively for in-vitro laboratory research use and are not for human consumption. Researchers should consult the published peer-reviewed literature cited throughout this article for complete experimental methodology and data.